

REFERENCES

- [1] Rangel M, “An overview of the marine natural products in clinical trials and on the market,” *Coast. J. Life Med.*, vol. 3, no. 6, 2015.
- [2] Harvey A. L, Edrada-Ebel R, and Quinn R. J, “The re-emergence of natural products for drug discovery in the genomics era,” *Nat. Rev. Drug Discov.*, vol. 14, no. 2, pp. 111–129, 2015.
- [3] Burgess J. G, “New and emerging analytical techniques for marine biotechnology,” *Curr. Opin. Biotechnol.*, vol. 23, no. 1, pp. 29–33, 2012.
- [4] Singh R. D, Mody S. K, Patel H. B, Devi S, Sarvaiya V. N, Patel H. A, and Patel B. R, “Antimicrobial Drug Discovery : Evident Shifting from Terrestrial to Marine Micro-organisms,” *Int. J. Curr. Microbiol. Appl. Sci.*, vol. 6, no. 5, pp. 2322–2327, 2017.
- [5] Pereira H, Custódio L, Rodrigues M. J, De Sousa C. B, Oliveira M, Barreira L, Neng N. D. R, Nogueira J. M. F, Alrokayan S. A, Mouffouk F, Abu-Salah K. M, Ben-Hamadou R, and Varela J, “Biological activities and chemical composition of methanolic extracts of selected autochthonous microalgae strains from the Red Sea,” *Mar. Drugs*, vol. 13, no. 6, pp. 3531–3549, 2015.
- [6] Suganya T, Varman M, Masjuki H. H, and Renganathan S, “Macroalgae and microalgae as a potential source for commercial applications along with biofuels production: A biorefinery approach,” *Renew. Sustain. Energy Rev.*, vol. 55, pp. 909–941, 2016.
- [7] El Gamal A. A, “Biological importance of marine algae,” *Saudi Pharm. J.*, vol. 18, no. 1, pp. 1–25, 2010.

- [8] Sahayaraj K, Protection C, and Xavier S, "Biological Values and Conservation of Marine Algae : an Over View," *Proc. "Conservation Sustain. Util. Mar. Resour.*, no. JANUARY, pp. 21–24, 2014.
- [9] Ramsey U. P, Bird C. J, Shacklock P. F, Laycock M. V, and Wright J. L. C, "Kainic acid and 1'-hydroxykainic acid from palmariales," *Nat. Toxins*, vol. 2, no. 5, pp. 286–292, 1994.
- [10] Mudit M and El Sayed K. A, "Cancer control potential of marine natural product scaffolds through inhibition of tumor cell migration and invasion," *Drug Discov. Today*, vol. 21, no. 11, pp. 1745–1760, 2016.
- [11] Lee J. C, Hou M. F, Huang H. W, Chang F. R, Yeh C. C, and Tang J. Y, "Marine Algal Natural Products Anti-oxidative, Anti-Inflammatory, and Anti Cancer Properties," *Ncbi*, pp. 1–7, 2013.
- [12] Sowmiya R, Balasubramani G, Deepak P, Aiswarya D, Ravikumar S, and Perumal P, "Characterization and screening of in vitro antimalarial and larvicidal activities of selected seaweeds from southeast coast of India against Plasmodium falciparum and Anopheles stephensi," *J. Coast. Life Med.*, vol. 5, no. 6, pp. 242–248, 2017.
- [13] Prasad K, Siddhanta A. K, Ganesan M, Ramavat B. K, Jha B, and Ghosh P. K, "Agars of Gelidiella acerosa of west and southeast coasts of India," *Bioresour. Technol.*, vol. 98, no. 10, pp. 1907–1915, 2007.
- [14] Ilavarasi K, Chermakani P, Arif Nisha S, Sheeja Malar D, and Pandima Devi K, "Antioxidant compounds in the seaweed Gelidiella acerosa protects human Peripheral Blood Mononuclear Cells against TCDD induced toxicity," *Drug Chem. Toxicol.*, vol. 38, no. 2, pp. 133–144, 2015.
- [15] Elsie B. H, Dhanarajan M. S, and Sudha P. N, "Invitro Screening of Secondary Metabolites and Antimicrobial Activities of Ethanol and Acetone Extracts From Red Seaweed Gelidium Acerosa," *Prevention*, vol. 2, no. 2, pp. 1–3, 2011.
- [16] Murugan K and Iyer V. V., "Differential growth inhibition of cancer cell lines and

- antioxidant activity of extracts of red, brown, and green marine algae,” *Vitr. Cell. Dev. Biol. - Anim.*, vol. 49, no. 5, pp. 324–334, 2013.
- [17] Ratnasooriya W. D, Premakumara G. A, and Tillekeratne L. M, “Post-coital contraceptive activity of crude extracts of Sri Lankan marine red algae.,” *Contraception*, vol. 50, no. 3, pp. 291–299, 1994.
- [18] Syad A. N, Shunmugiah K. P, and Kasi P. D, “Assessment of anticholinesterase activity of gelidiella acerosa: Implications for its therapeutic potential against alzheimer’s disease,” *Evidence-based Complement. Altern. Med.*, vol. 2012, 2012.
- [19] Vivek M, Kumar P. S, Steffi S, and Sudha S, “Biogenic silver nanoparticles by gelidiella acerosa extract and their antifungal effects,” *Avicenna J. Med. Biotechnol.*, vol. 3, no. 3, pp. 143–148, 2011.
- [20] Torre L. A, Bray F, Siegel R. L, Ferlay J, Lortet-tieulent J, and Jemal A, “Global Cancer Statistics, 2012,” *CA a cancer J. Clin.*, vol. 65, no. 2, pp. 87–108, 2015.
- [21] Kumari V, Kaushal K, Sharma AK, Mishra RC, Soni P, " Some Phytochemicals Found in Medicinal Plants Used in Cancer - A Review," *Med Chem (Los Angeles)*, vol. 8, pp. 423-425, 2015.
- [22] Kumar R, Lu S. K, Minchom A, Sharp A, Davidson M, Gunapala R, Yap T. A, Bhosle J, Popat S, and O’Brien M. E. R, “A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients,” *Cancer Chemother. Pharmacol.*, vol. 77, no. 2, pp. 375–383, 2016.
- [23] Travis W. D, Brambilla E, Noguchi M, Nicholson A. G, Geisinger K. R, Yatabe Y, Beer D. G, Powell C. A, Riely G. J, Van Schil P. E, Garg K, Austin J. H. M, Asamura H, Rusch V. W, Hirsch F. R, Scagliotti G, Mitsudomi T, Huber R. M, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier J. P, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang P. C, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B,

Johnson D, Kerr K, Kuriyama K, Lee J. S, Miller V. A, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz and D “International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma” *J. Thorac. Oncol.* vol. 6 no. 2 pp. 244–285 2011.

- [24] Fitzmaurice C, Allen C, Barber R. M, Barregard L, Bhutta Z. A, Brenner H, Dicker D. J, Chimed-Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar M. H, Hancock J, Hay R. J, Hunter-Merrill R, Huynh C, Hosgood H. D, Johnson C. O, Jonas J. B, Khubchandani J, Kumar G. A, Kutz M, Lan Q, Larson H. J, Liang X, Lim S. S, Lopez A. D, MacIntyre M. F, Marczak L, Marquez N, Mokdad A. H, Pinho C, Pourmalek F, Salomon J. A, Sanabria J. R, Sandar L, Sartorius B, Schwartz S. M, Shackelford K. A, Shibuya K, Stanaway J, Steiner C, Sun J, Takahashi K, Vollset S. E, Vos T, Wagner J. A, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed M. B, Alabed S, Alam N. K, Aldhahri S. F, Alem G, Alemayohu M. A, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem H. B, Barac A, Bedi N, Bensenor I, Berhane A, Bernabé E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castañeda-Orjuela C, Catalá-López F, Chiang P, Chibueze C, Chittheer A, Choi J. Y, Cowie B, Damtew S, Das Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries A. Y, Farvid M, Farzadfar F, Fernandes J, Fischer F, Ghiwot T. T, Gebru A, Gopalani S, Hailu A, Horino M, Horita N, Hussein A, Huybrechts I, Inoue M, Islami F, Jakovljevic M, James S, Javanbakht M, Jee S. H, Kasaeian A, Kedir M. S, Khader Y. S, Khang Y. H, Kim D, Leigh J, Linn S, Lunevicius R, El Razek H. M. A, Malekzadeh R, Malta D. C, Marcenes W, Markos D, Melaku Y. A, Meles K. G, Mendoza W, Mengiste D. T, Meretoja T. J, Miller T. R, Mohammad K. A, Mohammadi A, Mohammed S, Moradi-Lakeh M, Nagel G, Nand D, Le Nguyen Q, Nolte S, Ogbo F. A, Oladimeji K. E, Oren E, Pa M, Park E. K, Pereira D. M, Plass D, Qorbani M, Radfar A, Rafay A, Rahman M, Rana S. M, Søreide K, Satpathy M, Sawhney M, Sepanlou S. G, Shaikh M. A, She J, Shiue I, Shore H. R, Shrimme M. G, So S, Soneji S, Stathopoulou V,

- Stroumpoulis K, Sufiyan M. B, Sykes B. L, Tabarés-Seisdedos R, Tadese F, Tedla B. A, Tessema G. A, Thakur J. S, Tran B. X, Ukwaja K. N, Chudi Uzochukwu B. S, Vlassov V. V, Weiderpass E, Wubshet Terefe M, Yebyo H. G, Yimam H. H, Yonemoto N, Younis M. Z, Yu C, Zaidi Z, Zaki M. E. S, Zenebe Z. M, Murray C. J. L, and Naghavi M, “Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study Global Burden ,” *JAMA Oncol.*, vol. 3, no. 4, pp. 524–548, 2017.
- [25] Hamilton W, Peters T. J, Round A, and Sharp D, “What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study,” *Thorax*, vol. 60, no. 12, pp. 1059–1065, 2005.
- [26] Blanco-Prieto S, De Chiara L, Rodríguez-Girondo M, Vázquez-Iglesias L, Rodríguez-Berrocal F. J, Fernández-Villar A, Botana-Rial M. I, and De La Cadena M. P, “Highly sensitive marker panel for guidance in lung cancer rapid diagnostic units,” *Sci. Rep.*, vol. 7, pp. 1–11, 2017.
- [27] Howington J. A, Blum M. G, Chang A. C, Balekian A. A, and Murthy S. C, “Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines,” *Chest*, vol. 143, no. 5 SUPPL, p. e278S–e313S, 2013.
- [28] Reis C. D. B, Knust R. E, Cristina C, Pereira D. A, and Portela M. C, ““ Factors associated with non-small cell lung cancer treatment costs in a Brazilian public hospital ,”” pp. 1–10, 2018.
- [29] De Sá Junior P. L, Câmara D. A. D, Porcacchia A. S, Fonseca P. M. M, Jorge S. D, Araldi R. P, and Ferreira A. K, “The Roles of ROS in Cancer Heterogeneity and Therapy,” *Oxid. Med. Cell. Longev.*, pp.17-24, vol. 2017, 2017.
- [30] Patlevic P, Vašková J, Švorc P, Vaško L, and Švorc P, “Reactive oxygen species and antioxidant defense in human gastrointestinal diseases,” *Integr. Med.*

Res., vol. 5, no. 4, pp. 250–258, 2016.

- [31] Morry J, Ngamcherdtrakul W, and Yantasee W, “Oxidative stress in cancer and fibrosis: Opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles,” *Redox Biol.*, vol. 11, no. November 2016, pp. 240–253, 2017.
- [32] Augustyniak A, Bartosz G, Cipak A, Duburs G, Horáková L, Luczaj W, Majekova M, Odysseos A. D, Rackova L, Skrzydlewska E, Stefek M, Štrosová M, Tirzitis G, Venskutonis P. R, Viskupicova J, Vraka P. S, and Žarkovic N, “Natural and synthetic antioxidants: An updated overview,” *Free Radic. Res.*, vol. 44, no. 10, pp. 1216–1262, 2010.
- [33] Ghavami S, Hashemi M, Ande S. R, Yeganeh B, Xiao W, Eshraghi M, Bus C. J, Kadkhoda K, Wiechec E, Halayko A. J, and Los M, “Apoptosis and cancer: Mutations within caspase genes,” *J. Med. Genet.*, vol. 46, no. 8, pp. 497–510, 2009.
- [34] Liu X, He Y, Li F, Huang Q, Kato T. A, Hall R. P, and Li C. Y, “Caspase-3 Promotes Genetic Instability and Carcinogenesis,” *Mol. Cell*, vol. 58, no. 2, pp. 284–296, 2015.
- [35] Estornes Y, Aguilera M. A, Dubuisson C, De Keyser J, Goossens V, Kersse K, Samali A, Vandenabeele P, and Bertrand M. J. M, “RIPK1 promotes death receptor-independent caspase-8-mediated apoptosis under unresolved ER stress conditions,” *Cell Death Dis.*, vol. 5, no. 12, pp. 1–11, 2014.
- [36] Kovar .H, “Selective enhancer changes in osteosarcoma lung metastasis,” *Nat. Med.*, vol. 24, no. 2, pp. 126–127, 2018.
- [37] Rahman I, Biswas S. K, and Kode A, “Oxidant and antioxidant balance in the airways and airway diseases,” *Eur. J. Pharmacol.*, vol. 533, no. 1–3, pp. 222–239, 2006.
- [38] Dolcet X, Llobet D, Pallares J, and Matias-Guiu X, “NF-κB in development and progression of human cancer,” *Virchows Arch.*, vol. 446, no. 5, pp. 475–482,

2005.

- [39] Godwin P, Baird A. M, Heavey S, Barr M. P, O'Byrne K. J, and Gately K, "Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy," *Front. Oncol.*, vol. 3, no. May, pp. 1–10, 2013.
- [40] Engelman J. A, Luo J, and Cantley L. C, "The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism," *Nat. Rev. Genet.*, vol. 7, no. 8, pp. 606–619, 2006.
- [41] Raparia K, Villa C, DeCamp M. M, Patel J. D, and Mehta M. P, "Molecular Profiling in Non-Small Cell Lung Cancer: A Step Toward Personalized Medicine," *Arch. Pathol. Lab. Med.*, vol. 137, no. 4, pp. 481–491, 2013.
- [42] Markman B, Tao J. J, and Scaltriti M, "PI3K pathway inhibitors: better not left alone.," *Curr Pharm Des*, vol. 19, pp. 895–906, 2013.
- [43] Akinleye A, Avvaru P, Furqan M, Song Y, and Liu D, " Phosphatidyl Inositol 3 Kinase Inhibitors As Cancer Therapeutics," *J Hematol Oncol.*,vol. 6 , pp. 1–17, 2013.
- [44] Mayer I. A, Abramson V. G, Formisano L, Balko J. M, Estrada M. V, Sanders M. E, Juric D, Solit D, Berger M. F, Won H. H, Li Y, Cantley L. C, Winer E, and Arteaga C. L, "A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ERp/HER2 Metastatic Breast Cancer," *Clin. Cancer Res.*, vol. 23, no. 1, pp. 26–34, 2017.
- [45] Simmons T. L, Andrianasolo E, Mcphail K, Flatt P, and Gerwick W. H, "Marine natural products as anticancer drugs Minireview Marine natural products as anticancer drugs," *Mol. Cancer Ther.*, vol. 4, no. February, pp. 333–342, 2005.
- [46] Newland A. M, Pharm D, Li J. X, Wasco L. E, Aziz M. T, and Lowe D. K, "Brentuximab Vedotin : A CD30-Directed Antibody- Cytotoxic Drug Conjugate," 2013.
- [47] Erwin P. M, López-Legentil S, and Schuhmann P. W, "The pharmaceutical value of marine biodiversity for anti-cancer drug discovery," *Ecol. Econ.*, vol. 70, no. 2,

- pp. 445–451, 2010.
- [48] Harper J. L, Khalil I. M, Shaw L, Bourguet-Kondracki M. L, Dubois J, Valentin A, Barker D, and Copp B. R, “Structure-activity relationships of the bioactive thiazinoquinone marine natural products thiaplidiaquinones A and B,” *Mar. Drugs*, vol. 13, no. 8, pp. 5102–5110, 2015.
- [49] Perdicaris S, Vlachogianni T, and Valavanidis A, “Bioactive Natural Substances from Marine Sponges: New Developments and Prospects for Future Pharmaceuticals,” *Nat Prod Chem Res*, vol. 1, no. 1, pp. 1–8, 2013.
- [50] Krege S, Rexer H, Vom Dorp F, De Geeter P, Klotz T, Retz M, Heidenreich A, Kühn M, Kamradt J, Feyerabend S, Wülfing C, Zastrow S, Albers P, Hakenberg O, Roigas J, Fenner M, Heinzer H, and Schrader M, “Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05),” *BJU Int.*, vol. 113, no. 3, pp. 429–436, 2014.
- [51] Bendell J, Saleh M, Rose A. A. N, Siegel P. M, Hart L, Sirpal S, Jones S, Green J, Crowley E, Simantov R, Keler T, Davis T, and Vahdat L, “Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer,” *J. Clin. Oncol.*, vol. 32, no. 32, pp. 3619–3625, 2014.
- [52] Caplan S. L, Zheng B, Dawson-Scully K, White C. A, and West L. M, “Pseudopterosin a: Protection of synaptic function and potential as a neuromodulatory agent,” *Mar. Drugs*, vol. 14, no. 3, pp. 1–14, 2016.
- [53] Fan X, Xu N. J, and Shi J. G, “Bromophenols from the red alga *Rhodomela confervoides*,” *J. Nat. Prod.*, vol. 66, no. 3, pp. 455–458, 2003.
- [54] Ngo D. H and Kim S. K, “Sulfated polysaccharides as bioactive agents from marine algae,” *Int. J. Biol. Macromol.*, vol. 62, pp. 70–75, 2013.
- [55] Think P. D, Menshova R. V, Ermakova S. P, Anastyuk S. D, Ly B. M, and

- Zvyagintseva T. N, "Structural characteristics and anticancer activity of fucoidan from the brown alga *Sargassum mcclurei*," *Mar. Drugs*, vol. 11, no. 5, pp. 1453–1476, 2013.
- [56] Manojkumar K, "In vitro cancer chemopreventive properties of polysaccharide extract from the brown alga, *sargassum wightii*," *IOSR J. Pharm. Biol. Sci.*, vol. 8, no. 2, pp. 06–11, 2013.
- [57] A. A. Of, "International Journal of Innovative Pharmaceutical Sciences and Research ALGAE – A REVIEW," vol. 3, no. 72, pp. 72–89, 2015.
- [58] Al-Enazi N. M, Awaad A. S, Zain M. E, and Alqasoumi S. I, "Antimicrobial, antioxidant and anticancer activities of *Laurencia catarinensis*, *Laurencia majuscula* and *Padina pavonica* extracts," *Saudi Pharm. J.*, vol. 26, no. 1, pp. 44–52, 2017.
- [59] Plaza M, Cifuentes A, and Ibáñez E, "In the search of new functional food ingredients from algae," *Trends Food Sci. Technol.*, vol. 19, no. 1, pp. 31–39, 2008.
- [60] Guiry M. D, "How many species of algae are there?," *J. Phycol.*, vol. 48, no. 5, pp. 1057–1063, 2012
- [61] Reddy C. R. K, Salt C, Meenakshisundaram G, Salt C, Eswaran K, Salt C, Mantri V, and Salt C, "the Seaweed Resources of India," no. October 2015, 2014.
- [62] Indriatmoko Heriyanto, Limantara L, and Brotosudarmo T. H. P, "Composition of Photosynthetic Pigments in a Red Alga *Kappaphycus Alvarezii* Cultivated in Different Depths," *Procedia Chem.*, vol. 14, pp. 193–201, 2015.
- [63] Devi K. P, Suganthy N, Kesika P, and Pandian S. K, "Bioprotective properties of seaweeds: In vitro evaluation of antioxidant activity and antimicrobial activity against food borne bacteria in relation to polyphenolic content," *BMC Complement. Altern. Med.*, vol. 8, pp. 1–11, 2008.
- [64] Suganthy N, Nisha S. A, Pandian S. K, and Devi K. P, "Evaluation of *Gelidiella*

- acerosa, the red algae inhabiting South Indian coastal area for antioxidant and metal chelating potential," *Biomed. Prev. Nutr.*, vol. 3, no. 4, pp. 399–406, 2013.
- [65] Duraikannu K, Shameem Rani K, Anithajothi R, Umagowsalya G, and Ramakritinan C. M, "in-Vivo Anticancer Activity of Red Algae (Gelidiella Acerosa and Acanthophora Spicifera)," *Int. J. Pharm. Sci. Res.*, vol. 5, no. 8, pp. 3347–3352, 2014.
- [66] Nobel Surya Pandidurai R, Kalavathi K, and Perumal P, "Studies on antibacterial activity of seaweeds, Enteromorpha intestinalis (linnaeus) and Gelidiella acerosa (forsskal) from Puducherry and Rameswaram (Southeast Coast of India)," *Int. J. Pharma Bio Sci.*, vol. 5, no. 1, pp. 1139–1147, 2014.
- [67] Long J. S and Ryan K. M, "New frontiers in promoting tumour cell death: Targeting apoptosis, necroptosis and autophagy," *Oncogene*, vol. 31, no. 49, pp. 5045–5060, 2012.
- [68] Ganesan M and Kadalmani B, "A retrospective analysis of incidence of breast cancer at a tertiary care hospital in South India," *J. Acad. Ind. Res.*, vol. 4, no. 8, p. 199, 2016.
- [69] Parikh P, Ranade A, Govind B, Ghadyalpatil N, Singh R, Bharath R, Bhattacharyya G, Koyande S, Singhal M, Vora A, Verma A, and Hingmire S, "Lung cancer in India: Current status and promising strategies," *South Asian J. Cancer*, vol. 5, no. 3, p. 93, 2016.
- [70] Bobdey S, Sathwara J, Jain A, and Balasubramaniam G "Burden of cervical cancer and role of screening in India," *Indian J. Med. Paediatr. Oncol.*, vol. 37, no. 4, p. 278, 2016.
- [71] Dinesh S, "Cancer data in India show new patterns", *The Lancet Oncology*, vol 17, no. 7, p 272, 2016.
- [72] Chae Y. K, Anker J. F, Carneiro B. A, Chandra S, Kaplan J, Kalyan A, Santa-Maria C. A, Plataniias L. C, and Giles F. J, "Genomic landscape of DNA repair genes in cancer," *Oncotarget*, vol. 7, no. 17, 2016.

- [73] Guan X, "Cancer metastases: Challenges and opportunities," *Acta Pharm. Sin. B*, vol. 5, no. 5, pp. 402–418, 2015.
- [74] Van Nagell J. R, DePriest P. D, Ueland F. R, DeSimone C. P, Cooper A. L, McDonald J. M, Pavlik E. J, Kryscio R. J, Twickler D. M, Moschos E, Karlan B. Y, Platt L. D, a Fishman D, Cohen L, V Blank S, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I. I, Schwartz P. E, Siegel R, Naishadham D, Jemal A, Luis J, Sassone A, Meire H, Farrant P, Guha T, Granberg S a Norström, Wikland M, Ferrazzi E, Zanetta G, Fleischer A. C, Lyshchik A, Hirari M, Moore R. D, Abramson R. G, and Gallion H. H, "Ultrasound and assessment of ovarian cancer risk.," *Cancer*, vol. 37, no. 2, pp. 408–14, 2013.
- [75] Lazebnik Y, "What are the hallmarks of cancer?," *Nat. Rev. Cancer*, vol. 10, no. 4, pp. 232–233, 2010.
- [76] Du B and Shim J. S, "Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer," *Molecules*, vol. 21, no. 7, 2016.
- [77] Lamouille S, Xu J, and Derynck R, "Molecular mechanisms of epithelial-mesenchymal transition.," *Natl. Rev. Mol. Cell Biol.*, vol. 15, no. 3, pp. 178–196, 2014.
- [78] Haemmerle M, Taylor M. L, Gutschner T, Pradeep S, Cho M. S, Sheng J, Lyons Y. M, Nagaraja A. S, Dood R. L, Wen Y, Mangala L. S, Hansen J. M, Rupaimoole R, Gharpure K. M, Rodriguez-Aguayo C, Yim S. Y, Lee J. S, Ivan C, Hu W, Lopez-Berestein G, Wong S. T, Karlan B. Y, Levine D. A, Liu J, Afshar-Kharghan V, and Sood A. K, "Platelets reduce anoikis and promote metastasis by activating YAP1 signaling," *Nat. Commun.*, vol. 8, no. 1, 2017.
- [79] Albini A, Tosetti F, Li V. W, Noonan D. M, and Li W. W, "Cancer prevention by targeting angiogenesis," *Nat. Rev. Clin. Oncol.*, vol. 9, no. 9, pp. 498–509, 2012.
- [80] Yadav L, Puri N, Rastogi V, Satpute P, and Sharma V, "Tumour angiogenesis and angiogenic inhibitors: A review," *J. Clin. Diagnostic Res.*, vol. 9, no. 6, p. XE01-XE05, 2015.

- [81] Nicolini A, Ferrari P, Diodati L, and Carpi A, "Recent advances in comprehending the signaling pathways involved in the progression of breast cancer," *Int. J. Mol. Sci.*, vol. 18, no. 11, 2017.
- [82] Ahmad R and Dhawan P, "Cancer Stem Cell and Gastrointestinal Cancer: Current Status, Targeted Therapy and Future Implications," *Biochem. Pharmacol. Open Access*, vol. 5, no. 2, 2015.
- [83] Steeg P. S, "Targeting metastasis," *Nat. Rev. Cancer*, vol. 16, no. 4, pp. 201–218, 2016.
- [84] Juneja M, Kobelt D, Walther W, Voss C, Smith J, Specker E, Neuenschwander M, Gohlke B. O, Dahlmann M, Radetzki S, Preissner R, von Kries J. P, Schlag P. M, and Stein U, "Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1," *PLoS Biol.*, vol. 15, no. 6, pp. 1–28, 2017.
- [85] Wong R. S, "Apoptosis in cancer: from pathogenesis to treatment," *J. Exp. Clin. Cancer Res.*, vol. 30, no. 1, p. 87, 2011.
- [86] Marchand B, Arsenault D, Raymond-Fleury A, Boisvert F. M, and Boucher M. J, "Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells," *J. Biol. Chem.*, vol. 290, no. 9, pp. 5592–5605, 2015.
- [87] Faria M, Matos P, Pereira T, Cabrera R, Cardoso B. A, Bugalho M. J, and Silva A. L, "RAC1b overexpression stimulates proliferation and NF- κ B-mediated anti-apoptotic signaling in thyroid cancer cells," *PLoS One*, vol. 12, no. 2, p. e0172689, 2017.
- [88] Nakajima S, Kato H, Gu L, Takahashi S, Johno H, Umezawa K, and Kitamura M, "Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF- κ B suppression via reactive oxygen species and unfolded protein response.," *J. Immunol.*, vol. 190, no. 12, pp. 6559–69, 2013.
- [89] Fortin J and Mak T. W, "Targeting PI3K Signaling in Cancer: A Cautionary Tale of

- Two AKTs,” *Cancer Cell*, vol. 29, no. 4, pp. 429–431, 2016.
- [90] Janku F, “Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients,” *Cancer Treat. Rev.*, vol. 59, pp. 93–101, 2017.
- [91] Alberg A. J, Wallace K, Silvestri G. A, and Brock M. V, “Invited commentary: The etiology of lung cancer in men compared with women,” *Am. J. Epidemiol.*, vol. 177, no. 7, pp. 613–616, 2013.
- [92] Behera D, “SC17.03 Lung Cancer in India: Challenges and Perspectives,” *J. Thorac. Oncol.*, vol. 12, no. 1, pp. S114–S115, 2017.
- [93] Porta C, Paglino C, and Mosca A, “Targeting PI3K/Akt/mTOR Signaling in Cancer,” *Front. Oncol.*, vol. 4, no. April, pp. 1–11, 2014.
- [94] Adam E, Kim H. N, Gang E. J, Schnair C, Lee S, Lee S, Khazal S, Kosoyan O, Konopleva M, Parekh C, Bhojwani D, Wayne A. S, Abdel-Azim H, Heisterkamp N, and Kim Y. M, “The PI3K δ inhibitor idelalisib inhibits homing in an in vitro and in vivo model of B ALL,” *Cancers (Basel)*, vol. 9, no. 9, pp. 1–11, 2017.
- [95] Pons-Tostivint E, Thibault B, and Guillermet-Guibert J, “Targeting PI3K Signaling in Combination Cancer Therapy,” *Trends in Cancer*, vol. 3, no. 6, pp. 454–469, 2017.
- [96] Monteillier A, Allard P.-M, Gindro K, Wolfender J.-L, and Cuendet M, “Lung Cancer Chemopreventive Activity of Patulin Isolated from *Penicillium vulpinum*,” *Molecules*, vol. 23, no. 3, p. 636, 2018.
- [97] Chul Kwon M and Berns A, “Mouse models for lung cancer,” *Mol. Oncol.*, vol. 7, no. 2, pp. 165–177, 2013.
- [98] Tan A. C, Konczak I, Sze D. M.-Y, and Ramzan I, “Molecular Pathways for Cancer Chemoprevention by Dietary Phytochemicals,” *Nutr. Cancer*, vol. 63, no. 4, pp. 495–505, 2011.
- [99] González-Vallinas M, González-Castejón M, Rodríguez-Casado A, Ramírez de

- and Molina A, "Dietary phytochemicals in cancer prevention and therapy: A complementary approach with promising perspectives," *Nutr. Rev.*, vol. 71, no. 9, pp. 585–599, 2013.
- [100] Benetou V, Lagiou A, and Lagiou P, "Chemoprevention of cancer: current evidence and future prospects," *F1000Research*, vol. 4, pp. 1–10, 2015.
- [101] Rather R. A and Bhagat M, "Cancer Chemoprevention and Piperine: Molecular Mechanisms and Therapeutic Opportunities," *Front. Cell Dev. Biol.*, vol. 6, no. February, pp. 1–12, 2018.
- [102] Bunaciu R. P and Yen A, "Retinoid Chemoprevention: Who Can Benefit?," *Curr. Pharmacol. Reports*, vol. 1, no. 6, pp. 391–400, 2015.
- [103] Baldi A, "Computational approaches for drug design and discovery: An overview," *Syst. Rev. Pharm.*, vol. 1, no. 1, p. 99, 2010.
- [104] López-Camacho E, García Godoy M. J, Nebro A. J, and Aldana-Montes J. F, "JMetalCpp: Optimizing molecular docking problems with a C++ metaheuristic framework," *Bioinformatics*, vol. 30, no. 3, pp. 437–438, 2014.
- [105] Guedes I. A, de Magalhães C. S, and Dardenne L. E, "Receptor-ligand molecular docking," *Biophys. Rev.*, vol. 6, no. 1, pp. 75–87, 2014.
- [106] Marciniak K, Pawelczak B, Latocha M, Skrzypek L, Maciazek-Jurczyk M, Boryczka S, and Supuran C. T, "Synthesis, anti-breast cancer activity, and molecular docking study of a new group of acetylenic quinolinesulfonamide derivatives," *Molecules*, vol. 22, no. 2, pp. 1–19, 2017.
- [107] H. S and Begum F. M, "Characterisation, in Silico and in Vitro Determination of Antidiabetic and Anti Inflammatory Potential of Ethanolic Extract of Sargassum Wightii.," *Asian J. Pharm. Clin. Res.*, vol. 10, no. 4, p. 297, 2017.
- [108] Pagadala N. S, Syed K, and Tuszynski J, "Software for molecular docking: a review," *Biophys. Rev.*, vol. 9, no. 2, pp. 91–102, 2017.
- [109] Ruiz-Carmona S, Alvarez-Garcia D, Foloppe N, Garmendia-Doval A. B, Juhos

- S, Schmidtke P, Barril X, Hubbard R. E, and Morley S. D, “rDock: A Fast, Versatile and Open Source Program for Docking Ligands to Proteins and Nucleic Acids,” *PLoS Comput. Biol.*, vol. 10, no. 4, pp. 1–7, 2014.
- [110] Goldstone V. J, G M. A, Kubota A, Zanette J, Parente T, Jönsson M. E, Nelson D. R, and Stegeman J. J, “Identification and developmental expression of the full complement of Cytochrome P450 genes in Zebrafish.” vol. 11, p. 643, 2010.
- [111] Bootorabi F, Manouchehri H, Changizi R, Barker H, Palazzo E, Saltari A, Parikka M, Pincelli C, and Aspatwar A, “Zebrafish as a model organism for the development of drugs for skin cancer,” *Int. J. Mol. Sci.*, vol. 18, no. 7, pp. 1–15, 2017.
- [112] Hill A. J, Teraoka H, Heideman W, and Peterson R. E, “Zebrafish as a model vertebrate for investigating chemical toxicity,” *Toxicol. Sci.*, vol. 86, no. 1, pp. 6–19, 2005.
- [113] Santoriello C and Zon L. I, “Science in medicine Hooked ! Modeling human disease in zebrafish,” *J. Clin. Invest.*, vol. 122, no. 7, pp. 2337–2343, 2012.
- [114] K. Howe, M. Clark, C. Torroja, J. Torrance, C. Berthelot, M. Muffato, J. E. Collins, S. Humphray, K. McLaren, L. Matthews, S. McLaren, I. Sealy, M. Caccamo, C. Churcher, C. Scott, J. C. Barrett, R. Koch, and E. Al., “The zebrafish reference genome sequence and its relationship to the human genome,” *Nature*, vol. 496, no. 7446, pp. 498–503, 2013.
- [115] Phillips J. B and Westerfield M, “Zebrafish models in translational research: tipping the scales toward advancements in human health,” *Dis. Model. Mech.*, vol. 7, no. 7, pp. 739–743, 2014.
- [116] MacRae C. A and Peterson R. T, “Zebrafish as tools for drug discovery,” *Nat. Rev. Drug Discov.*, vol. 14, no. 10, pp. 721–731, 2015.
- [117] Li M, Zhao L, Page-McCaw P. S, and Chen W, “Zebrafish Genome Engineering Using the CRISPR-Cas9 System.” *Trends Genet.*, vol. 32, no. 12, pp. 815–827, 2016.

- [118] Saltari A, Truzzi F, Quadri M, Lotti R, Palazzo E, Grisendi G, Tiso N, Marconi A, and Pincelli C, "CD271 Down-Regulation Promotes Melanoma Progression and Invasion in Three-Dimensional Models and in Zebrafish," *J. Invest. Dermatol.*, vol. 136, no. 10, pp. 2049–2058, 2016.
- [119] Stoletov K, and Klemke R, "Catch of the day: Zebrafish as a human cancer model," *Oncogene*, vol. 27, no. 33, pp. 4509–4520, 2008.
- [120] Wyatt R. A, Trieu N. P. V, and Crawford B. D "Zebrafish xenograft: An evolutionary experiment in tumour biology," *Genes (Basel)*., vol. 8, no. 9, 2017.
- [121] Idilli A. I, Precazzini F, Mione M. C, and Anelli V "Zebrafish in translational cancer research: Insight into leukemia, melanoma, Glioma and endocrine tumor biology," *Genes (Basel)*., vol. 8, no. 9, 2017.
- [122] Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, and Pangalos M. N, "Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework," *Nat. Rev. Drug Discov.*, vol. 13, no. 6, pp. 419–431, 2014.
- [123] Yang F, Gao C, Wang P, Zhang G.-J, and Chen Z "Fish-on-a-chip: microfluidics for zebrafish research," *Lab Chip*, vol. 16, no. 7, pp. 1106–1125, 2016.
- [124] Low L.A and Tagle D.A," Tissue Chips to aid drug development and modeling for rare diseases ", *Expert Opin Orphan Drugs*,vol. 4,no.11, pp 1113–1121, 2016
- [125] Choudhary A, Naughton L, Montánchez I, Dobson A, and Rai D "Current Status and Future Prospects of Marine Natural Products (MNPs) as Antimicrobials," *Mar. Drugs*, vol. 15, no. 9, p. 272, 2017.
- [126] Mohammadi A, Amrollahi H, Malek F, and Nazari H "In vitro antibacterial activity and phytochemical analysis of some medicinal plants," *J. Med. Plants Res.*, vol. 8, no. 3, pp. 186–194, 2014.
- [127] Harborne J.B, *Phytochemical Methods; A Guide to Modern Techniques of Plant Analysis*, vol. 3, 1998.

- [128] Singleton V. L, Rossi J. A, and Jr J, "Colorimetry of Total Phenolics With Phosphomoybdc-Phosphotungstic Acid Reagents," *Am J Enol Viticult.*, no. 16, pp. 144–158, 1965.
- [129] Zhishen J, Mengcheng T, Jiaming W, "Determination of flavonoid content in mulberry and their scavenging effects on superoxide radicals", *Food chemistry*, vol. 64, pp. 555-559, 1999.
- [130] Packialakshmi N and Naziya S, "Fourier Transform Infrared Spectroscopy Analysis of Various Solvent extracts of *Caralluma fimbriata*," *Asian J. Biomed. Pharm. Sci.*, vol. 4, no. 36, pp. 20–25, 2014.
- [131] Kardani K, Gurav N, Solanki B, Patel P, and Patel B, "RP-HPLC method development and validation of gallic acid in Polyherbal tablet formulation," *J. Appl. Pharm. Sci.*, vol. 3, no. 5, pp. 37–42, 2013.
- [132] Blois M.S, "Biochim.Biophys. Acta", Nature Publishing Group, vol. 181, pp. 165 1958.
- [133] Hoye T.R and Zhao H, "A method for easily determining coupling constant values: An addendum to 'a practical guide to first-order multiplet analysis in ¹H NMR spectroscopy,'" *J. Org. Chem.*, vol. 67, no. 12, pp. 4014–4016, 2002.
- [134] Mosmann B, "MTT-Assay: Cell Viability" 1983, La Fontaine," p. 2004, 2005.
- [135] Cummings B. S, Wills L. P, and Schnellmann R. G, "Measurement of Cell Death in Mammalian Cells," *Curr Protoc Pharmacol*, vol. 1, no. Lemasters 1999, pp. 1–30, 2004.
- [136] Crowley L. C, Marfell B. J, Scott A. P, and Waterhouse N. J, "Quantitation of apoptosis and necrosis by annexin V binding, propidium iodide uptake, and flow cytometry," *Cold Spring Harb. Protoc.*, vol. 2016, no. 11, pp. 953–957, 2016.
- [137] Dimmick I, "Multiple flow cytometry applications: use of DAPI," *Biomed. Sci.*, no. August, pp. 541–543, 2011.
- [138] Park J. H, Jang Y.-J, Choi Y. J, Jang J. W, Kim J.-H, Rho Y.-K, Kim I. J, Kim

- H.-J, Leem M. J, Lee and S.-T “Fisetin Inhibits Matrix Metalloproteinases and Reduces Tumor Cell Invasiveness and Endothelial Cell Tube Formation,” *Nutr. Cancer*, vol. 65, no. 8, pp. 1192–1199, 2013.
- [139] Rafehi H, Orłowski C, Georgiadis G. T, Ververis K, El-Osta A, Karagiannis and T. C, “Clonogenic Assay: Adherent Cells,” *J. Vis. Exp.*, no. 49, pp. 3–6, 2011.
- [140] Laware S. L., “Original Research Article Sequential Extraction of Plant Metabolites,” vol. 4, no. 2, pp. 33–38, 2015.
- [141] Machu L , Misurcova L, Ambrozova J, Orsavova J, Mlcek J, Sochor J, and Jurikova T, " Phenolic Content and Antioxidant Capacity in Algal Food Products", *Molecules*, vol. 20, pp.1118-1133, 2015.
- [142] Joseph S. V, Edirisinghe I, and Burton-Freeman B. M “Fruit Polyphenols: A Review of Anti-inflammatory Effects in Humans,” *Crit. Rev. Food Sci. Nutr.*, vol. 56, no. 3, pp. 419–444, 2016.
- [143] Vineet K. M, Ajit K. P, V. K, Nachimuthu S. K, Bhim and P. S, “Antimicrobial and antioxidant activities of *Blumea lanceolaria* (Roxb.),” *J. Med. Plants Res.*, vol. 9, no. 4, pp. 84–90, 2015.
- [144] Khan H. Y, Zubair H, Ullah M. F, Ahmad A, and Hadi S. M “A Prooxidant Mechanism for the Anticancer and Chemopreventive Properties of Plant Polyphenols.,” *Curr. Drug Targets*, p. 2012, 2012.
- [145] Kim H. J, Choi H. K, Moon J. Y, Kim Y. S, Mosaddik A, and Cho S. K “Comparative Antioxidant and Antiproliferative Activities of Red and White Pitayas and Their Correlation with Flavonoid and Polyphenol Content,” *J. Food Sci.*, vol. 76, no. 1, pp. 1–8, 2011.
- [146] Bucar F, Wube A, and Schmid M, “Natural product isolation – how to get from biological material to pure compounds,” *Nat. Prod. Rep.*, vol. 30, no. 4, p. 525, 2013.
- [147] Sumayya S.S and Murugan K, “Phytochemical Screening, RP-HPLC and FTIR Analysis of *Kappaphycus alvarezii* (Doty) Doty EX P.C Silva: Macro Red Algae,”

- J. Pharmacogn. Phytochem.*, vol. 6, no. 1, pp. 325–330, 2017.
- [148] Kannan S, “FT-IR and EDS analysis of the seaweeds *Sargassum wightii* and *Gracilaria corticata* (red algae),” *Int J Curr Microbiol Appl Sci*, vol. 3, no. 4, pp. 341–351, 2014.
- [149] El-Saadi M. W, Williams-Hart T, Salvatore B. A, and Mahdavian E “Use of in-silico assays to characterize the ADMET profile and identify potential therapeutic targets of fusarochromanone, a novel anti-cancer agent,” *Silico Pharmacol.*, vol. 3, no. 1, p. 6, 2015.
- [150] Shi Y, “Mechanisms of caspase activation and inhibition during apoptosis,” *Mol. Cell*, vol. 9, no. 3, pp. 459–470, 2002.
- [151] Blanchard H, Kodandapani L, Mittl P. R. E, Di Marco S, Krebs J. F, Wu J. C, Tomaselli K. J, and Grütter M. G, “The three-dimensional structure of caspase-8: An initiator enzyme in apoptosis,” *Structure*, vol. 7, no. 9, pp. 1125–1133, 1999.
- [152] Wei M. C, Lindsten T, Mootha V. K, Weiler S, Gross A, Ashiya M, Thompson C. B, and Korsmeyer S. Jr, “tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c,” *Genes Dev.*, vol. 14, no. 16, pp. 2060–2071, 2000.
- [153] Garner T. P, Reyna D. E, Priyadarshi A, Chen H, Li S, Wu Y, Ganesan Y. T, Malashkevich V. N, Almo S. S, Emily and H “Activation Pathway,” vol. 63, no. 3, pp. 485–497, 2017.
- [154] Adams J. M., “The Bcl-2 Protein Family: Arbiters of Cell Survival,” *Science (80-)*, vol. 281, no. 5381, pp. 1322–1326, 1998.
- [155] Ahmed M, and Jamil K, “Scientific Reports,” *Structure*, vol. 1, no. 1, pp. 2–5, 2012.
- [156] Manion M. K, O’Neill J. W, Giedt C. D, Kim K. M, Zhang K. Y. Z, and Hockenbery D. M “Bcl-XL Mutations Suppress Cellular Sensitivity to Antimycin A,” *J. Biol. Chem.*, vol. 279, no. 3, pp. 2159–2165, 2004.

- [157] Thorpe L. M., Yuzugullu H., and Zhao J. J., "PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting," *Nat. Rev. Cancer*, vol. 15, no. 1, pp. 7–24, 2015.
- [158] Block T. M, Rawat S, Brosgart C. L, and Francisco S, "HHS Public Access," vol. 22, no. 2, pp. 69–81, 2017.
- [159] Stambolic V, and Woodgett J.R, "Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration," *Trends Cell Biol.*, vol. 16, no. 9, pp. 461–466, 2006.
- [160] Huang B. X, Akbar M, Kevala K, Kim and H. Y, "Phosphatidylserine is a critical modulator for Akt activation," *J. Cell Biol.*, vol. 192, no. 6, pp. 979–992, 2011.
- [161] Blake J. F, Kallan N. C, Xiao D, Xu R, Bencsik J. R, Skelton N. J, Spencer K. L, Mitchell I. S, Woessner R. D, Gloor S. L, Risom T, Gross S. D, Martinson M, Morales T. H, Vigers G. P. A, Brandhuber and B. J "Discovery of pyrrolopyrimidine inhibitors of Akt," *Bioorganic Med. Chem. Lett.*, vol. 20, no. 19, pp. 5607–5612, 2010.
- [162] Dajani R, Fraser E, Roe S. M, Young N, Good V, Dale T. C, and Pearl L. H "Crystal structure of glycogen synthase kinase 3B: Structural basis for phosphate-primed substrate specificity and autoinhibition," *Cell*, vol. 105, no. 6, pp. 721–732, 2001.
- [163] Ter Haar E, Coll J. T, Austen D. A, Hsiao H. M, Swenson L, Jain and J, "Structure of GSK3 β reveals a primed phosphorylation mechanism," *Nat. Struct. Biol.*, vol. 8, no. 7, pp. 593–596, 2001.
- [164] Lee J.-O, Yang H, Georgescu M.-M, Di Cristofano A, Maehama T, Shi Y, Dixon J. E, Pandolfi P, Pavletich and N. P, "Crystal Structure of the PTEN Tumor Suppressor," *Cell*, vol. 99, no. 3, pp. 323–334, 1999.
- [165] Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi and M "Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: Possible sequence progression

- from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary,” *Cancer Res.*, vol. 60, no. 24, pp. 7052–7056, 2000.
- [166] Hayden M. S and Ghosh S, “Signaling to NF- κ B,” *Genes Dev.*, vol. 18, pp. 2195–2224, 2004.
- [167] Gilmore T. D., “Introduction to NF- κ B: Players, pathways, perspectives,” *Oncogene*, vol. 25, no. 51, pp. 6680–6684, 2006.
- [168] Revathi Mani B, and Venkateswari R, “Insilico analysis on the effect of rutin bioflavonoid and chemotherapeutic drug cyclophosphamide on nuclear factor kappa-b protein expression,” *Int. J. Pharma Bio Sci.*, vol. 5, no. 1, pp. 560–569, 2014.
- [169] Xu G, Cirilli M, Huang Y, Rich R. L, Myszka D. G, and Wu H, “Covalent inhibition revealed by the crystal structure of the caspase-8/p35 complex,” *Nature*, vol. 410, no. 6827, pp. 494–497, 2001.
- [170] Zhao G, Zhu Y, Eno C. O, Liu Y, DeLeeuw L, Burlison J. A, Chaires J. B, Trent J. O, and Li C, “Activation of the Proapoptotic Bcl-2 Protein Bax by a Small Molecule Induces Tumor Cell Apoptosis,” *Mol. Cell. Biol.*, vol. 34, no. 7, pp. 1198–1207, 2014.
- [171] Nithya G and Sakthisekaran S, “In Silico Docking Studies on the Anti-Cancer Effect of Thymoquinone on Interaction With Pten- a Regulator of Pi3K/ Akt Pathway,” *Asian J Pharm. Clin Res*, vol. 8, no. 1, pp. 8–11, 2015.
- [172] Hernández C, Ascacio-Valdés VJ, De la Garza H, Wong-Paz J, Aguilar C. N., Martínez-Ávila G. C., Castro-López C., and Aguilera-Carbó A., “Polyphenolic content, in vitro antioxidant activity and chemical composition of extract from *Nephelium lappaceum* L. (Mexican rambutan) husk,” *Asian Pac. J. Trop. Med.*, vol. 10, no. 12, pp. 1201–1205, 2017.
- [173] Sugathakumar Adithya E, Santha Lakshmi M, Hephzibah Christabel P, Mahalingam Sasikumar and J “In vitro antioxidant, anti-lipid peroxidation activities and HPLC analysis of methanol extracts from bark and stem of *Mahonia*

- leschenaultia takeda,” *Asian J. Plant Sci. Res.*, vol. 3, no. 2, pp. 116–126, 2013.
- [174] Benmehdi H, Behilil A, Memmou F, and Amrouche A “Free radical scavenging activity, kinetic behaviour and phytochemical constituents of *Aristolochia clematitis* L. roots,” *Arab. J. Chem.*, vol. 10, pp. S1402–S1408, 2017.
- [175] McCubrey J. A, Steeman L, Chappell W, Abrams S, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino M, Candido S, Libra M, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martell and Ai, “Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades,” *Oncotarget*, vol. 3, no. 9, pp. 954–987, 2012.
- [176] Roy R, Yang J, and Moses M. A, “Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer,” *J. Clin. Oncol.*, vol. 27, no. 31, pp. 5287–5297, 2009.
- [177] Das A, Monteiro M, Barai A, Kumar S, Sen and S, “MMP proteolytic activity regulates cancer invasiveness by modulating integrins,” *Sci. Rep.*, vol. 7, no. 1, pp. 1–13, 2017.
- [178] Dong W, Li H, and Zhang Y, “Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer,” *Acta Biochim.*, vol. 1, no. October, pp. 840–848, 2011.
- [179] Lakka S. S, Jasti S. L, Gondi C, Boyd D, Chandrasekar N, Dinh D. H, Olivero W. C, Gujrati M, Rao and J. S “Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro,” *Oncogene*, vol. 21, no. 36, pp. 5601–5608, 2002.
- [180] Beg A.A and Baltimore D, "An Essential Role for NF-KB in Preventing TNF-a-Induced Cell Death", *SCIENCE*, vol. 274, pp. 782-784,1996.
- [181] Currie A. H. W. A. A. R., KERR J. F. R., “Apoptosis: a Basic Biological Phenomenon With Wide- Ranging Implications in Tissue Kinetics,” *J. Intern. Med.*, vol. 258, no. 6, pp. 479–517, 1972.

- [182] Liu G, Zou H, Luo T, Long M, Bian J, Liu X, Gu J, Yuan Y, Song R, Wang Y, Zhu J, Liu and Z, "Caspase-dependent and caspase-independent pathways are involved in cadmium-induced apoptosis in primary rat proximal tubular cell culture," *PLoS One*, vol. 11, no. 11, pp. 1–17, 2016.
- [183] Rajavel T, Mohankumar R, Archunan G, Ruckmani K, and Devi K. P, "Beta sitosterol and Daucosterol (phytosterols identified in *Grewia tiliaefolia*) perturbs cell cycle and induces apoptotic cell death in A549 cells," *Sci. Rep.*, vol. 7, no. 1, pp. 1–15, 2017.
- [184] Sultan A, Khalil M, Sami B, Alkhuriji and A, "Quercetin induces apoptosis in triple-negative breast cancer cells via inhibiting fatty acid synthase and β -catenin," *Int J Clin Exp*, vol. 10, no. 1, pp. 156–172, 2017.
- [185] Maurer U, Preiss F, Brauns-Schubert P, Schlicher L, Charvet and C, "GSK-3 - at the crossroads of cell death and survival," *J. Cell Sci.*, vol. 127, no. 7, pp. 1369–1378, 2014.
- [186] Kurosu T, Nagao T, Wu N, Oshikawa G, Miura and O, "Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis," *PLoS One*, vol. 8, no. 11, 2013.
- [187] Kitagishi Y, Nakanishi A, Ogura Y., and Matsuda S., "Dietary regulation of PI3K / AKT / GSK-3 β pathway in Alzheimer ' s disease," *Alzheimers. Res. Ther.*, vol. 6, no. 3, pp. 1–7, 2014.
- [188] Kwon M. J. and Nam T. J., "A polysaccharide of the marine alga *Capsosiphon fulvescens* induces apoptosis in AGS gastric cancer cells via an IGF-IR-mediated PI3K/Akt pathway," *Cell Biol. Int.*, vol. 31, no. 8, pp. 768–775, 2007.
- [189] Choo G. S, Lee H. N, Shin S. A, Kim H. J, Jung and J. Y "Anticancer effect of fucoidan on DU-145 prostate cancer cells through inhibition of PI3K/Akt and MAPK pathway expression," *Mar. Drugs*, vol. 14, no. 7, 2016.
- [190] Ray M. R. and Jablons D. M., "Hall marks of metastasis", *Lung Cancer*

- Metastasis, vol. 410, pp. 29–47, 2010.
- [191] Merchant N, Nagaraju G. P, Rajitha B, Lammata S, Jella K. K, uchwald Z. S, akka S. S, Ali and A. N, “Matrix metalloproteinases: Their functional role in lung cancer,” *Carcinogenesis*, vol. 38, no. 8, pp. 766–780, 2017.
- [192] Li H, Qiu Z, Li F, Wang and C “The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis,” *Oncol. Lett.*, vol. 14, no. 5, pp. 5865–5870, 2017.
- [193] Webb A. H, Gao B. T, Goldsmith Z. K, Irvine A. S, Saleh N, Lee R. P, Lendermon J. B, Bheemreddy R, Zhang Q, Brennan R. C, Johnson D, Steinle J. J, Wilson M. W, Morales-Tirado and V. M, “Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma,” *BMC Cancer*, vol. 17, no. 1, pp. 1–11, 2017.
- [194] Drzewiecka-Jędrzejczyk M., Wlazel R., Terlecka M., and Jabłoński S., Wlazel R., Terlecka M., and Jabłoński S., “Serum metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in lung carcinoma patients,” *J. Thorac. Dis.*, vol. 9, no. 12, pp. 5306–5313, 2017.
- [195] Blanco-Prieto S, Barcia-Castro L, Páez de la Cadena M, Rodríguez-Berrocal F. J, Vázquez-Iglesias L, Botana-Rial M. I, Fernández-Villar A, De Chiara and L, “Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis,” *BMC Cancer*, vol. 17, no. 1, pp. 1–8, 2017.
- [196] Kucuksayan H, and Akgun S, “PI3K/Akt/NF-κB Signalling Pathway on NSCLC Invasion,” *Med. Chem. (Los. Angeles)*., vol. 6, no. 4, pp. 234–238, 2016.
- [197] Chen L, Yao Y, Sun L, and Tang J “Galectin-1 promotes tumor progression via NF-κB signaling pathway in epithelial ovarian cancer,” *J. Cancer*, vol. 8, no. 18, pp. 3733–3741, 2017.
- [198] Sun Y. S., Zhao Z., and Zhu H. P., “Hispolon inhibits TPA-induced invasion by reducing MMP-9 expression through the NF-κB signaling pathway in MDA-MB-231 human breast cancer cells,” *Oncol. Lett.*, vol. 10, no. 1, pp. 536–542, 2015.

- [199] Coussens L. M. and Werb Z., "Inflammation and cancer," *Nature*, vol. 420, no. 6917, pp. 860–867, 2002.
- [200] Crusz S.M and Balkwill F.R, "Inflammation and cancer: Advances and new agents," *Nat. Rev. Clin. Oncol.*, vol. 12, no. 10, pp. 584–596, 2015.
- [201] Grover V, Kapoor A, Sehgal K, and Kaur G, "Chronic Inflammation and Carcinogenesis – Emerging Role of Chronic Inflammatory Periodontal Disease," *Cancer Res. Front.*, vol. 2, no. 2, pp. 200–225, 2016.
- [202] Galdiero M. R, Marone G, and Mantovani A, "Cancer Inflammation and Cytokines," *Cold Spring Harb. Perspect. Biol.*, p. a028662, 2017.
- [203] Colotta F, Allavena P, Sica A, Garlanda C, and Mantovani A "Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability," *Carcinogenesis*, vol. 30, no. 7, pp. 1073–1081, 2009.
- [204] Lin H. W, Liu C. W, Yang D. J, Chen C. C, Chen S. Y, Tseng J. K, Chang T. J, Chang and Y., "Dunaliella salina alga extract inhibits the production of interleukin-6, nitric oxide, and reactive oxygen species by regulating nuclear factor- κ B/Janus kinase/signal transducer and activator of transcription in virus-infected RAW264.7 cells," *J. Food Drug Anal.*, vol. 25, no. 4, pp. 908–918, 2017.
- [205] Kim M. E, Jung Y. C, Jung I, Lee H. W, Youn H. Y, Lee and J. S "Anti-inflammatory effects of ethanolic extract from *Sargassum horneri* (Turner) C. Agardh on lipopolysaccharide-stimulated macrophage activation via NF- κ B pathway regulation," *Immunol. Invest.*, vol. 44, no. 2, pp. 137–146, 2015.
- [206] Royuela M, Rodriguez-Berriguete G, Fraile B, Paniagua and R TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate.," *Histol. Histopathol.*, vol. 23, no. 10, pp. 1279–1290, 2008.
- [207] Sarbassov D. D, Guertin D. A, Ali S. M, and Sabatini D. M, "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex," *Science (80-.)*, vol. 307, no. 5712, pp. 1098–1101, 2005.
- [208] Blunt J. W, Copp B. R, Keyzers R. A, Munro M. H. G, and Prinsep M. R

- “Marine natural products,” *Nat. Prod. Rep.*, vol. 31, no. 2, p. 160, 2014.
- [209] Malve H, “Exploring the ocean for new drug developments: Marine pharmacology,” *J. Pharm. Bioallied Sci.*, vol. 8, no. 2, p. 83, 2016.
- [210] Suganthi N, Nisha S. A, Pandian S. K, and Devi K. P, “Evaluation of *Gelidiella acerosa*, the red algae inhabiting South Indian coastal area for antioxidant and metal chelating potential,” *Biomed. Prev. Nutr.*, vol. 3, no. 4, pp. 399–406, 2013.
- [211] Ghaffari M, Taheri A, Bavi Z, Soheili and F, “Assessment of Antioxidant Properties of Red Seaweed *Gelidiella acerosa* of Chabahar Coastal Waters, Iran,” *Qom Univ Med Sci Qom Univ Med Sci J*, vol. 10, no. 11, pp. 34–41, 2017.
- [212] Xie P, Fujii I, Zhao J, Shinohara M, and Matsukura M, “A novel polysaccharide derived from algae extract induces apoptosis and cell cycle arrest in human gastric carcinoma MKN45 cells via ROS/JNK signaling pathway,” *Int. J. Oncol.*, vol. 49, no. 4, pp. 1561–1568, 2016.
- [213] Mancinelli R., Carpino G., Petrungaro S., Mammola C. L., Tomaipitınca L., Filippini A., Facchiano A., Ziparo E., and Giampietri C., “Multifaceted roles of GSK-3 in cancer and autophagy-related diseases,” *Oxid. Med. Cell. Longev.*, vol. 2017, pp. 33-39, 2017.
- [214] Ugolkov A., Gaisina I, Zhang J. S., D. D. Billadeau D. D., White K., Kozikowski A., Jain S., Cristofanilli M., Giles F., O’Halloran T., Cryns V. L., and Mazar A. P., “GSK-3 inhibition overcomes chemoresistance in human breast cancer,” *Cancer Lett.*, vol. 380, no. 2, pp. 384–392, 2016.
- [215] Hermida M. A., Dinesh Kumar J, and Leslie N. R., “GSK3 and its interactions with the PI3K/AKT/mTOR signalling network,” *Adv. Biol. Regul.*, vol. 65, pp. 5–15, 2017.
- [216] Manning B. D. and Toker A. “AKT/PKB Signaling: Navigating the Network,” *Cell*, vol. 169, no. 3, pp. 381–405, 2017.
- [217] Zhang Y. and Chen Q., “Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer,” *Brazilian J. Med. Biol. Res.*, vol.

50, no. 6, pp. 6–13, 2017.

- [218] Yang D. J, Lin J. T., Chen Y. C., Liu S. C, Lu F. J, Chang T. J., Wang M, Lin H. W, and Chang Y. Y, “Suppressive effect of carotenoid extract of *Dunaliella salina* alga on production of LPS-stimulated pro-inflammatory mediators in RAW264.7 cells via NF- κ B and JNK inactivation,” *J. Funct. Foods*, vol. 5, no. 2, pp. 607–615, 2013.